FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081508721> ?p ?o ?g. }

• W3081508721 abstract "Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RA) have previously shown improved measures of memory and reduced phospho‐tau burden in preclinical animal models relevant to progressive cognitive impairment (Hansen. J Alzheimers Dis .2015;46:877‐88; Hansen. Brain Res .2016;1634:158‐70). Liraglutide and semaglutide are structurally similar GLP‐1 RAs associated with potent glucose‐lowering effect, body weight loss and cardiovascular benefits shown in large cardiovascular outcomes trials (CVOTs) (Marso. N Engl J Med .2016;375:311‐22; Marso. N Engl J Med .2016;375:1834‐44; Husain. N Engl J Med .2019;381:841‐51). In order to investigate the potential effects of GLP‐1 RA on dementia in a clinical setting, a post‐hoc analysis was conducted based on pooled data from three CVOTs. Method LEADER, SUSTAIN 6 and PIONEER 6 were randomised, double‐blind, multicentre, placebo‐controlled CVOTs evaluating the cardiovascular effect of liraglutide or semaglutide vs. placebo, added to standard of care. The trials included patients with type 2 diabetes and established or high risk of cardiovascular disease. A post‐hoc analysis on pooled data from the three CVOTs was considered appropriate due to the similarities in trial design, patient population and treatment effects. Across all trials 15,820 patients with median follow‐up of 3.6 years were included in this analysis. Dementia‐related adverse events (AEs) were identified using Standardised MedDRA (version 21.1) Query for “dementia” narrow search terms. AE data collection across the trials differed in line with the regulatory requirements at the time of trial conduct. In LEADER and PIONEER 6 only serious AEs were systematically collected, while all AEs were collected in SUSTAIN 6. A time‐to‐event analysis based on the Cox proportional‐hazards model using treatment as covariate was used to estimate the hazard ratio for developing dementia. Result Across the three CVOTs, 15 GLP‐1 RA‐treated patients and 32 placebo‐treated patients were identified with development of dementia (Figure). Post‐hoc analysis on the pooled data showed a significant estimated hazard ratio of 0.47 [0.25; 0.86] 95%CI in favour of the GLP‐1 RA treatment versus placebo. Conclusion Post‐hoc analysis based on pooled data from three double‐blinded CVOTs suggests, albeit with a low number of events, a reduced risk of dementia with liraglutide or semaglutide treatment in patients with type 2 diabetes." @default.
• W3081508721 created "2020-09-01" @default.
• W3081508721 creator A5003038598 @default.
• W3081508721 creator A5032708452 @default.
• W3081508721 creator A5033388327 @default.
• W3081508721 creator A5040628721 @default.
• W3081508721 creator A5045328872 @default.
• W3081508721 creator A5052313246 @default.
• W3081508721 creator A5066004762 @default.
• W3081508721 creator A5087165669 @default.
• W3081508721 creator A5087431344 @default.
• W3081508721 creator A5088627727 @default.
• W3081508721 creator A5088993988 @default.
• W3081508721 creator A5090437675 @default.
• W3081508721 date "2020-12-01" @default.
• W3081508721 modified "2023-10-14" @default.
• W3081508721 title "Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes" @default.
• W3081508721 doi "https://doi.org/10.1002/alz.042909" @default.
• W3081508721 hasPublicationYear "2020" @default.
• W3081508721 type Work @default.
• W3081508721 sameAs 3081508721 @default.
• W3081508721 citedByCount "11" @default.
• W3081508721 countsByYear W30815087212021 @default.
• W3081508721 countsByYear W30815087212022 @default.
• W3081508721 countsByYear W30815087212023 @default.
• W3081508721 crossrefType "journal-article" @default.
• W3081508721 hasAuthorship W3081508721A5003038598 @default.
• W3081508721 hasAuthorship W3081508721A5032708452 @default.
• W3081508721 hasAuthorship W3081508721A5033388327 @default.
• W3081508721 hasAuthorship W3081508721A5040628721 @default.
• W3081508721 hasAuthorship W3081508721A5045328872 @default.
• W3081508721 hasAuthorship W3081508721A5052313246 @default.
• W3081508721 hasAuthorship W3081508721A5066004762 @default.
• W3081508721 hasAuthorship W3081508721A5087165669 @default.
• W3081508721 hasAuthorship W3081508721A5087431344 @default.
• W3081508721 hasAuthorship W3081508721A5088627727 @default.
• W3081508721 hasAuthorship W3081508721A5088993988 @default.
• W3081508721 hasAuthorship W3081508721A5090437675 @default.
• W3081508721 hasBestOaLocation W30815087211 @default.
• W3081508721 hasConcept C126322002 @default.
• W3081508721 hasConcept C134018914 @default.
• W3081508721 hasConcept C142724271 @default.
• W3081508721 hasConcept C197934379 @default.
• W3081508721 hasConcept C204787440 @default.
• W3081508721 hasConcept C27081682 @default.
• W3081508721 hasConcept C2777180221 @default.
• W3081508721 hasConcept C2779134260 @default.
• W3081508721 hasConcept C2779483572 @default.
• W3081508721 hasConcept C2781308992 @default.
• W3081508721 hasConcept C2908647359 @default.
• W3081508721 hasConcept C2909862629 @default.
• W3081508721 hasConcept C3017906399 @default.
• W3081508721 hasConcept C555293320 @default.
• W3081508721 hasConcept C67761136 @default.
• W3081508721 hasConcept C71924100 @default.
• W3081508721 hasConcept C95190672 @default.
• W3081508721 hasConcept C99454951 @default.
• W3081508721 hasConceptScore W3081508721C126322002 @default.
• W3081508721 hasConceptScore W3081508721C134018914 @default.
• W3081508721 hasConceptScore W3081508721C142724271 @default.
• W3081508721 hasConceptScore W3081508721C197934379 @default.
• W3081508721 hasConceptScore W3081508721C204787440 @default.
• W3081508721 hasConceptScore W3081508721C27081682 @default.
• W3081508721 hasConceptScore W3081508721C2777180221 @default.
• W3081508721 hasConceptScore W3081508721C2779134260 @default.
• W3081508721 hasConceptScore W3081508721C2779483572 @default.
• W3081508721 hasConceptScore W3081508721C2781308992 @default.
• W3081508721 hasConceptScore W3081508721C2908647359 @default.
• W3081508721 hasConceptScore W3081508721C2909862629 @default.
• W3081508721 hasConceptScore W3081508721C3017906399 @default.
• W3081508721 hasConceptScore W3081508721C555293320 @default.
• W3081508721 hasConceptScore W3081508721C67761136 @default.
• W3081508721 hasConceptScore W3081508721C71924100 @default.
• W3081508721 hasConceptScore W3081508721C95190672 @default.
• W3081508721 hasConceptScore W3081508721C99454951 @default.
• W3081508721 hasIssue "S9" @default.
• W3081508721 hasLocation W30815087211 @default.
• W3081508721 hasLocation W30815087212 @default.
• W3081508721 hasOpenAccess W3081508721 @default.
• W3081508721 hasPrimaryLocation W30815087211 @default.
• W3081508721 hasRelatedWork W2920262859 @default.
• W3081508721 hasRelatedWork W2974001637 @default.
• W3081508721 hasRelatedWork W3029655646 @default.
• W3081508721 hasRelatedWork W3033586845 @default.
• W3081508721 hasRelatedWork W3033877044 @default.
• W3081508721 hasRelatedWork W3042095004 @default.
• W3081508721 hasRelatedWork W3066769783 @default.
• W3081508721 hasRelatedWork W3081508721 @default.
• W3081508721 hasRelatedWork W3174691046 @default.
• W3081508721 hasRelatedWork W4287953211 @default.
• W3081508721 hasVolume "16" @default.
• W3081508721 isParatext "false" @default.
• W3081508721 isRetracted "false" @default.
• W3081508721 magId "3081508721" @default.
• W3081508721 workType "article" @default.